

- Urinary incontinence
 after prostatectomy, 583
 in elderly, 80–81, 81f
 postmenopausal hormone therapy and, 2384t
 in terminally ill patient, 69t
 treatment of, 81
- Urinary tract
 bleeding from. *See* Hematuria
 congenital abnormalities of, 1855, 1871, 1871t
- Urinary tract infections (UTIs), **861**
 approach to the patient, 863–864, 865f
 in burn patient, 166e-2
 in cancer patient, 490
 clinical features of, 863–864, 865f
 complicated, 861, 864, 867–868
 definitions in, 861
 delirium in, 169
 in diabetes mellitus, 2427
 diagnosis of, 864–866, 865f
 differential diagnosis of, 864
 epidemiology of, 861–862
 etiology of, 862
 A. baumannii, 1037
 Citrobacter, 1035
 E. coli, 1028
 enterococcal, 973, 975t
 K. pneumoniae, 1032, 1871
 Morganella, 1035
 nontyphoidal *Salmonella*, 1054
 P. aeruginosa, 1045t, 1047
 Proteus, 1033, 1871
 Providencia, 1035, 1871
 S. aureus, 959
 S. saprophyticus, 960
 tuberculous, 1110
 genetic considerations in, 863
 global considerations in, 862, 866
 health care–associated, 868, 913–914, 914t
 in MS, 2672
 nephrolithiasis and, 1871
 pathogenesis of, 862–863, 862f
 in pregnancy, 49–50, 867
 prevention of, 868
 prognosis of, 868
 pyelonephritis. *See* Pyelonephritis
 recurrent, 861
 renal abscess and, 851
 risk factors for, 861–862
 in transplant recipient, 924
 treatment of
 acute cystitis in women, 866–867, 867t
 asymptomatic bacteriuria, 868
 Candida infection, 868
 catheter-associated, 868, 914
 complicated infection, 867–868
 drug resistance and, 862, 866
 E. coli infection, 1029
 in men, 867
 in pregnancy, 867
 urinary tract obstruction in, 1873
- Urinary tract obstruction, **1871**
 acute kidney injury and, 291–292, 1804–1805, 1804f
 in cancer, 1790
 clinical features of, 289t, 1872–1873
 diagnosis of, 289t, 1873, 1873f
 diuresis following, 1874
 etiology of, 1871–1872, 1871t
 hyperkalemia in, 307
 hyponatremia in, 299
 hypovolemia in, 297
 pathophysiology of, 1872–1873, 1872t
 prognosis of, 1874
 treatment of, 1873–1874
- Urinary urea nitrogen, 462–463, 464t
- Urinary D-xylose test, 1938
- Urination, painful
 in cystitis. *See* Cystitis
 in interstitial cystitis bladder pain syndrome.
 See Interstitial cystitis/bladder pain syndrome
 in men, 60e-1
 in urinary tract infections. *See* Urinary tract infections (UTIs)
 in women, 60e-1
- Urine
 abnormalities of, 289t, **293**. *See also* Urinalysis
 casts, 62e-11–12f, 294
 crystals, 62e-12f, 435e-2
 hematuria. *See* Hematuria
 polyuria. *See* Polyuria
 proteinuria. *See* Proteinuria
 pyuria, 294
 black, 434e-4
 nephrolithiasis risk and, 1867
 osmolality of, 291t, 294–295, 301, 304
 sodium loss in, 298, 301
 tea/cola colored, 279, 462e-1
 Urine bilirubin, 280, 1996, 1998t, 2000
 Urine-derived stem cells, 453t
 Urine dipstick test, 280, 864
 Urine output, 95e-1
 Urobilinogens, 280, 2000
 Urobilins, 280
 Urocanic acid, 388
 Urocanic aciduria, 434e-2t
 Urochromes, 1819
 UROD gene mutations, 2530–2531
 Urogenital secretions, specimen collection and transport, 150e-4t
 Urography, 1873
 Urokinase, 758–759
 Urokinase-type plasminogen activator (u-PA), 402, 402f, 758
 Uromodulin. *See* Tamm-Horsfall protein
 Uroplakins, 145e-2, 145e-5
 Uroporphyrinogen (URO) decarboxylase, 2523t, 2525
 Uroporphyrinogen III (URO) synthase, 2523t, 2524–2525
 UROS gene, 2523t
 Ursodeoxycholic acid (UDCA)
 for gallstone dissolution, 2080
 for gallstone prevention during rapid weight loss, 2078
 for primary biliary cirrhosis, 2061
 for primary sclerosing cholangitis, 2062, 2086
- Urticaria, **363, 2117**
 aquagenic, 2118
 cholinergic, 363, 363t, 2119
 classification of, 2117, 2118t
 clinical features of, 135, 341t, 2118–2119
 distribution, 341t
 morphology, 355
 papules and plaques, 25e-9f, 76e-4f, 342, 343f
 cold, **363, 363t, 422, 2118–2119**
 contact, 2118
 definition of, 2117
 diagnosis of, 342, 2119
 drug-induced, 377, 381
 etiology of, 135, 363t, 2117–2118, 2118t
 local heat, 2118
 pathophysiology of, 2118–2119
 physical, **363, 363t**
 predisposing factors for, 2117–2118, 2118t
 pressure, 2118
 solar, **363, 363t, 2118**
 in systemic mastocytosis, 2120. *See also* Mastocytosis
 treatment of, 381, 2119–2120
- Urticarial vasculitis, 132t, 135, **363, 363t**
- Urticaria pigmentosa, 363, 363t, 367
- Urushiol, 345
- U.S. Department of Health and Human Services,
 Action Plan to Prevent Healthcare-Associated Infections, 912
- U.S. President's Emergency Plan for AIDS Relief (PEPFAR), 8
- U.S. Preventive Services Task Force, 28–30, 29t
- Usher's syndrome, 220, 222t
- Ustekinumab, 348t, 1962, 2173, 2177
- Usutu virus, 1307t, 1315
- Uterus, disorders of
 amenorrhea in, 336, 337f
 endometrial cancer. *See* Endometrial cancer
 endometriosis. *See* Endometriosis
 gas gangrene, 831
 pelvic pain in, 338
 sarcoma, 596, 597
 treatment of, 336
- UTIs. *See* Urinary tract infections (UTIs)
- Uukuniemi virus, 1310t
- Uveitis
 in ankylosing spondylitis, 2171
 anterior, 200, 373e-7, 373e-8t, 2171
 in Behçet's syndrome, 2194
 in IBD, 1958
 paraneoplastic, 614t, 619
 posterior, 200
 in secondary syphilis, 1135
 treatment of, 2173
 with tubulointerstitial nephritis, 1857–1858
 in Whipple's disease, 1093, 1094
- Uvula, bifid, 1443
- Uvulopalatopharyngoplasty, 1727
- U wave, 1453
- V**
- Vaccine(s), **785**. *See also* Immunization; *specific vaccines*
 administration of, 791–792, 791f
 adverse event reporting, 792
 cancer prevention and, 476–477
 contraindications to, 786, 789–790t
 development of, genomics in, 775–776, 778
 documentation of, 792
 for elderly, 84
 future trends in, 793
 global considerations in, 785
 hypersensitivity to, 790
 impact of, 785–786, 785t
 information statements, 790–791
 precautions for, 789–790t
 routinely administered in U.S., 785t
 safety monitoring, 792
 storage and handling of, 791
 tumor, 103e-20
 for viral infections, 214e-9
 viral vectors for, 214e-9
- Vaccine Adverse Event Reporting System (VAERS), 792
- Vaccine Information Sheet (VIS), 790–791
- Vaccine-preventable disease, 785, 785t, 786
- Vaccine Safety Datalink Project, 792
- Vaccinia vaccine, 261e-7, 261e-7t
- Vaccinia virus, 214e-8. *See also* Smallpox
- Vacuum constriction device, 329
- VAERS (Vaccine Adverse Event Reporting System), 792
- Vagabonds' disease, 2746
- Vagina
 blind, 335
 cancer, 1198
 congenital absence of, 2357
 dilatation of, 336
 discharge from, 872–873, 873t, 875–876.
 See also Vulvovaginal infections
 microbiota of, 86e-5, 863
- Vaginal ring, monthly, 2391
- Vaginal septum, 335
- Vagotomy, 1925–1927, 1925f
- Vagus nerve
 anatomy of, 213f
 disorders of, 2649
 examination of, 2538
 stimulation, for depression, 2717
 in taste sensation, 213
- Valacyclovir
 action of, 215e-6
 adverse effects of, 215e-7
 for Bell's palsy, 2648
 for herpes zoster, 215e-3–4t, 215e-7, 832t, 1186, 2657
 for HSV infections, **1181, 1182t**
 esophagitis, 1910
 genital, 215e-3t, 215e-7, 832t
 mucocutaneous, 215e-3t
 for HSV prophylaxis in HIV infection, 1181, 1252t